Training for Men Undergoing Androgen Deprivation Therapy.
NCT06449664
Summary
The goal of this clinical trial is to evaluate the effects of a newly developed training concept on men with prostate cancer undergoing androgen deprivation therapy (ADT). The main questions it aims to answer are: * How feasible and safe is the new training concept? * How efficient is the training concept to counteract side effects caused by ADT? Researchers will compare the new training concept with usual care to evaluate how efficient the training concept is to counteract the ADT-related side effects. Participants in the intervention group will perform the new training concept twice weekly for 12 weeks. Participants in the control group will only receive usual care. All participants will visit the laboratory at baseline and after 6 and 12 weeks to measure the primary and secondary outcomes.
Eligibility
Inclusion Criteria: 1. signed informed consent 2. histologically confirmed localised or locally advanced prostate cancer 3. planned radiotherapy in combination with ADT for at least six months (unfavorable intermediate risk and high-risk prostate cancer) with curative intent and with no known metastasis. Exclusion Criteria: 1. very high risk localised prostate cancer planned for radiotherapy and ADT plus abiraterone and cortisone 2. localized prostate cancer planned for radiotherapy without ADT 3. on-going or previously treated with ADT or other hormonal treatments 4. have any contraindications to physical testing/exercise as per the ACSM guidelines 5. unable to comply with study procedures
Conditions2
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06449664